

Docket No. 13761-0754

1841
RECEIVED
FEB 04 2002
TECH CENTER 1600/2900

Certificate of Mailing/Transmission (37 C.F.R. § 1.8(a)):

[X] Pursuant to 37 C.F.R. § 1.8, I hereby certify that this paper and all enclosures are being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington D.C. 20231.

[] Pursuant to 37 C.F.R. § 1.6(d), I hereby certify that this paper and all enclosures are being sent via facsimile on the date indicated below to the attention of Examiner _____ at Facsimile No. _____ at _____ a.m./p.m.

Dated: January 17, 2002 Name of Person Certifying: Barrett
Printed Name: LAER BARRETT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brooks, et al. Assignee: University of Southern California
Filing Date: 06/01/2001 Examiner: Unassigned
Serial No.: 09/872,165 Group Art Unit: 1641
Title: **NOVEL METHOD AND COMPOSITION FOR INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH USING COMPOUNDS BASED ON A SEQUENCE WITHIN MMP-2**

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached Form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application.

I. Timing of the Information Disclosure Statement:

This Information Disclosure Statement is filed:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months after the filing date of the application or within three months after the date of entry of the national stage of a PCT application as set forth in 37 C.F.R. § 1.491.
- ☐ Before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114.
- ☒ Before the mailing of a first Office action on the merits. In the event, however, that an Office Action has crossed in the mail with this Information Disclosure Statement:

02/04/2002 MWOLDER1 00000041 501192 09872165

01 FC:126 180.00 CH

☒ the Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No. 13761-0754 for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

☐ a statement as specified in 37 C.F.R. § 1.97(e) is provided below.

This Information Disclosure Statement is filed:

☐ After the first Office Action and more than three months after the application's filing date; or PCT national stage date of entry filing, or after the mailing of a first Office Action after the filing of a request for continued examination, but, as far as is known to the undersigned, prior to the mailing date of either a final rejection or a notice of allowance, whichever occurs first, and

☐ the Commissioner is hereby authorized to charge Deposit Account No. [] for the fee (\$180) set forth in 37 C.F.R. § 1.17(p) and any additional required fees.

☐ a statement as specified in 37 C.F.R. § 1.97(e) is provided below.

This Information Disclosure Statement is filed:

☐ After the mailing date of either a final rejection or a notice of allowance, whichever occurred first, but on or before the payment of an issue fee, and is accompanied by the fee (\$180.00) set forth in 37 C.F.R. § 1.17(i)(1) and a certification as specified in 37 C.F.R. § 1.97(e), as checked below. This document is to be considered as a petition requesting consideration of the Information Disclosure Statement.

Pursuant to 37 C.F.R. § 1.97(e), the undersigned certifies that:

☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

II. Copies of the Cited Items:

☒ Copies of all of the items listed on the attached Form PTO-1449 are enclosed.

☐ Copies of only the following items listed on the attached Form PTO-1449 are enclosed: _____.

- ☐ Copies of those items which are marked with an asterisk (*) in the attached Form PTO-1499 are not supplied because they were previously cited by or submitted to the Patent Office in a prior Application No. _____, filed _____ and relied upon in this application for an earlier filing date under 35 U.S.C. § 120. See 37 C.F.R. § 1.98(d).
- ☐ Copies of those items which are marked with an asterisk (**) in the attached Form PTO-1499 were cited in a foreign examination report in a related case. A copy of the search report and the cited references not already of record in this application are attached hereto.

III. Concise Explanation of Relevance:

- ☒ A concise explanation of relevance of the items listed on Form PTO-1449 is not given.
- ☐ A concise explanation of relevance of [some of] the items listed on Form PTO-1449 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references (copy attached).

IV. Conclusion:

Citation of the above documents shall not be construed as:

1. an admission that the documents are necessarily prior art with respect to the instant invention;
2. a representation that a search has been made, other than as described above; or
3. an admission that the information cited herein is, or is considered to be, material to patentability as defined in § 1.56(b).

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO 1449 with initials or other appropriate marks.

The Commissioner is hereby authorized to charge Deposit Account No. 50-1192, Docket No.: 13761-0754 for any additional fees required in connection with the filing of this Information Disclosure Statement.

DATE: January 15, 2002

Respectfully submitted,

By: 

Rajiv Yadav, Ph.D., Esq.
Registration No. 43,999

McCutchen, Doyle, Brown & Enersen, LLP
Three Embarcadero Center, 18th Floor
San Francisco, California 94111
Telephone: (415) 393-2000
Telefax: (415) 393-2286

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

13761-0754

SERIAL NO.

09/872,165

INVENTOR


Brooks, et al.

FILING DATE

06/01/2001

GROUP ART UNIT

1641



RECEIVED
 FEB 04 2002
 TECH CENTER 1600/2500

REFERENCE DESIGNATIONS U.S. PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	NAME	Class	Subclass	Filing Date If Appropriate
	A1.						
	A2.						
	A3.						

FOREIGN PATENT DOCUMENTS

EXAM'R INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	Subclass	TRANSLAT'N	
							yes	no
	B1							
	B3							
	B2							
	B4							

OTHER ART (Include Author, Title, Date, Pertinent Pages, etc.)

	C1	Folkman, J. and Shing, Y., "Angiogenesis," <i>The Journal of Biological Chemistry</i> , 267(16): 10931-10934, (1992)
	C2	Folkman, J. and Klagsbrun, M., "Angiogenic Factors," <i>Science</i> , 235: 442-447, (1987)
	C3	Folkman, J., "How is Blood Vessel Growth Regulated in Normal and Neoplastic Tissue?," <i>Cancer Research</i> , 46: 467-473, (1986)
	C4	Folkman, J., "What is the Evidence that Tumors are Angiogenesis Dependent?," <i>Journal of the National Cancer Institute</i> , 82: 4-6, (1989)
	C5	Weidner, N., et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma," <i>The New England Journal of Medicine</i> , 324(1): 1-8, (1991)
	C6	Varner, J. A., Brooks, P. C., and Cheres, D. A., "Review: The Integrin $\alpha_v\beta_3$: Angiogenesis and Apoptosis," <i>Cell Adh. Commun.</i> , 3, 367-374, (1995)
	C7	Gasparini, G. and Harris, A L., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More than a New Prognostic Tool," <i>J. Clin. Oncol.</i> , 13(3): 765-782, (1995)
	C8	Greene, T.H. and Wuts, P. G. M., "The Role of Protective Groups in Organic Synthesis," <i>Protective Groups in Organic Synthesis</i> , 2nd edition, John Wiley & Sons, New York, 1-9, (1991)
	C9	Berge, S.M., et al., "Pharmaceutical Salts," <i>J. Pharmaceutical Sciences</i> , 66(1): 1-19, (1997)
	C10	Cahn, R.S., et al., "Specification of Molecular Chirality," <i>Angew. Chem. Int. Ed. Engl.</i> , 5(4): 385-415, (1966)
	C11	IUPAC Commission on Nomenclature of Organic Chemistry, et al., "Nomenclature of α -Amino Acids (Recommendations, 1974)," <i>Biochemistry</i> , 14(2): 449-462, (1975)
	C12	Stewart, J.M. and Young, J. D., "The Chemistry of Solid Phase Peptide Synthesis," <i>Solid Phase Peptide Synthesis</i> , W. H. Freeman Co., San Francisco, 1-26, (1963)
	C13	Meienhofer, J., "Peptide Synthesis: A Review of the Solid-Phase Method," <i>Hormonal Proteins and Peptides</i> , vol. 2, Academic Press, New York, 46-267, (1973)
	C14	Schroeder, G. and Lupke, K., "The Peptides," vol. 1, <i>Academic Press</i> , New York, 1-51; 317-412, (1965)
	C15	Ausprunk, D. et al., "Vascularization of Normal and Neoplastic Tissues Grafted to the Chick Chorioallantois," <i>Am. J. Pathol.</i> , 79:597-618, (1975)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant(s).

**LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT(S)' INFORMATION DISCLOSURE
STATEMENT**

(Use several sheets if necessary)

ATTY. DOCKET NO.

13761-0754

SERIAL NO.

09/872,16

INVENTOR


Brooks, et al.

FILING DATE

06/01/2001

GROUP ART UNIT

1641



RECEIVED
FEB 04 2002
TECH CENTER 16012900

C16	Ossowski, L., et al., "Experimental Model for Quantitative Study of Metastasis," <i>Cancer Res.</i> , 40:2300-2309, (1980)
C17	D'Amato, R.J., et al., "Thalidomide is an Inhibitor of Angiogenesis," <i>Proc. Natl. Acad. Sci.</i> , 91:4082-4085, (1994)
C18	Yan, H.-C., et al., "Human/Severe Combined Immunodeficient Mouse Chimeras: An Experimental In Vivo Model System to Study the Regulation of Human Endothelial Cell-Leukocyte Adhesion Molecules," <i>J. Clin. Invest.</i> , 91:986-996, (1993)
C19	Poste, G., et al., "Lipid Vesicles as Carriers for Introducing Biologically Active Materials into Cells," <i>Methods in Cell Biology</i> , Vol. XIV, Academic Press, New York, 33-71, (1975).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance *and* not considered. Include copy of this form with next communication to Applicant(s).